Cargando…
Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature
BACKGROUND: High-grade gliomas (HGG) with BRAFV600E mutation represent a unique subset of central nervous system tumors. Targeted therapies including BRAF and MEK inhibitors are now being explored as possible new treatment options. METHODS: We report an 18-year-old female with a grade 3 pleomorphic...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772816/ https://www.ncbi.nlm.nih.gov/pubmed/36567957 http://dx.doi.org/10.1093/noajnl/vdac174 |
_version_ | 1784855062285123584 |
---|---|
author | Arbour, Gabrielle Ellezam, Benjamin Weil, Alexander G Cayrol, Romain Vanan, Magimairajan Issai Coltin, Hallie Larouche, Valérie Erker, Craig Jabado, Nada Perreault, Sébastien |
author_facet | Arbour, Gabrielle Ellezam, Benjamin Weil, Alexander G Cayrol, Romain Vanan, Magimairajan Issai Coltin, Hallie Larouche, Valérie Erker, Craig Jabado, Nada Perreault, Sébastien |
author_sort | Arbour, Gabrielle |
collection | PubMed |
description | BACKGROUND: High-grade gliomas (HGG) with BRAFV600E mutation represent a unique subset of central nervous system tumors. Targeted therapies including BRAF and MEK inhibitors are now being explored as possible new treatment options. METHODS: We report an 18-year-old female with a grade 3 pleomorphic xanthoastrocytoma treated upfront with dabrafenib and trametinib. We also conducted a systematic literature review of patients with HGG and BRAFV600E mutations treated with BRAF inhibitors. RESULTS: Despite local recurrences resected surgically, the patient has been on dabrafenib and trametinib for more than 54 months. Thirty-two patients with HGG and BRAFV600E mutations treated with BRAF inhibitors were retrieved through our systematic review of the literature. Only 1 young patient with an anaplastic ganglioglioma was treated upfront with a BRAF inhibitor with a curative intent. Best response reported with radiation therapy and systemic therapy was a stable disease (SD) for 18 patients (56.3%) and progressive disease (PD) for 9 patients (28.1%). Responses to treatment regimens that included BRAF inhibitors were reported in 31 patients and included 4 complete responses (12.9%), 23 partial responses (74.2%), 2 SDs (6.5%), and 2 PDs (6.5%). CONCLUSIONS: Our patient had durable disease control with dabrafenib and trametinib. Given favorable responses reported in patients with HGG treated with BRAF inhibitors, we believe that upfront targeted therapy is a possible treatment approach that should be studied in the context of a clinical trial. |
format | Online Article Text |
id | pubmed-9772816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97728162022-12-22 Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature Arbour, Gabrielle Ellezam, Benjamin Weil, Alexander G Cayrol, Romain Vanan, Magimairajan Issai Coltin, Hallie Larouche, Valérie Erker, Craig Jabado, Nada Perreault, Sébastien Neurooncol Adv Meta-Analysis BACKGROUND: High-grade gliomas (HGG) with BRAFV600E mutation represent a unique subset of central nervous system tumors. Targeted therapies including BRAF and MEK inhibitors are now being explored as possible new treatment options. METHODS: We report an 18-year-old female with a grade 3 pleomorphic xanthoastrocytoma treated upfront with dabrafenib and trametinib. We also conducted a systematic literature review of patients with HGG and BRAFV600E mutations treated with BRAF inhibitors. RESULTS: Despite local recurrences resected surgically, the patient has been on dabrafenib and trametinib for more than 54 months. Thirty-two patients with HGG and BRAFV600E mutations treated with BRAF inhibitors were retrieved through our systematic review of the literature. Only 1 young patient with an anaplastic ganglioglioma was treated upfront with a BRAF inhibitor with a curative intent. Best response reported with radiation therapy and systemic therapy was a stable disease (SD) for 18 patients (56.3%) and progressive disease (PD) for 9 patients (28.1%). Responses to treatment regimens that included BRAF inhibitors were reported in 31 patients and included 4 complete responses (12.9%), 23 partial responses (74.2%), 2 SDs (6.5%), and 2 PDs (6.5%). CONCLUSIONS: Our patient had durable disease control with dabrafenib and trametinib. Given favorable responses reported in patients with HGG treated with BRAF inhibitors, we believe that upfront targeted therapy is a possible treatment approach that should be studied in the context of a clinical trial. Oxford University Press 2022-11-19 /pmc/articles/PMC9772816/ /pubmed/36567957 http://dx.doi.org/10.1093/noajnl/vdac174 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Meta-Analysis Arbour, Gabrielle Ellezam, Benjamin Weil, Alexander G Cayrol, Romain Vanan, Magimairajan Issai Coltin, Hallie Larouche, Valérie Erker, Craig Jabado, Nada Perreault, Sébastien Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title_full | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title_fullStr | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title_full_unstemmed | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title_short | Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature |
title_sort | upfront braf/mek inhibitors for treatment of high-grade glioma: a case report and review of the literature |
topic | Meta-Analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772816/ https://www.ncbi.nlm.nih.gov/pubmed/36567957 http://dx.doi.org/10.1093/noajnl/vdac174 |
work_keys_str_mv | AT arbourgabrielle upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT ellezambenjamin upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT weilalexanderg upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT cayrolromain upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT vananmagimairajanissai upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT coltinhallie upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT larouchevalerie upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT erkercraig upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT jabadonada upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature AT perreaultsebastien upfrontbrafmekinhibitorsfortreatmentofhighgradegliomaacasereportandreviewoftheliterature |